Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Academic Article uri icon



  • The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1.0 and 1.3 mg/m(2)), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow-up (median >5 years). One- and 5-year survival rates were 82% and 32%, respectively, in the 1.0 mg/m(2) group (n = 28), and 81% and 45%, respectively, in the 1.3 mg/m(2) group (n = 26). Notable survival, response, and time-to-progression data suggest that a bortezomib starting dose of 1.3 mg/m(2) is preferred. If bortezomib dose reduction is required, the 1.0 mg/m(2) dose still offers patients a substantial survival benefit.

publication date

  • September 6, 2008



  • Antineoplastic Agents
  • Boronic Acids
  • Multiple Myeloma
  • Pyrazines


Scopus Document Identifier

  • 54849413402

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2141.2008.07359.x

PubMed ID

  • 18783399

Additional Document Info


  • 143


  • 4